Compare OXM & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | BWAY |
|---|---|---|
| Founded | 1942 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Apparel | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.3M | 674.2M |
| IPO Year | 1994 | N/A |
| Metric | OXM | BWAY |
|---|---|---|
| Price | $45.32 | $14.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $38.00 | $13.25 |
| AVG Volume (30 Days) | ★ 245.2K | 152.7K |
| Earning Date | 06-10-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,477,834,000.00 | N/A |
| Revenue This Year | $2.85 | $309.69 |
| Revenue Next Year | $2.63 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.57 | $10.21 |
| 52 Week High | $56.34 | $26.63 |
| Indicator | OXM | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 38.16 |
| Support Level | $35.94 | $11.90 |
| Resistance Level | $48.02 | $14.65 |
| Average True Range (ATR) | 2.23 | 0.54 |
| MACD | 0.36 | -0.18 |
| Stochastic Oscillator | 61.85 | 20.34 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.